Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Treatment of *Helicobacter pylori* infection (in combination with antibiotics)
* Zollinger-Ellison syndrome
* Prevention of NSAID-induced gastric ulcers
## Adult Dosing
**GERD and Erosive Esophagitis:**
* Oral: 40 mg once daily.
* Intravenous (IV): 40 mg once daily.
**_H. pylori_ Eradication:**
* Oral: 40 mg twice daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily for 7-14 days.
**Zollinger-Ellison Syndrome:**
* Oral: Starting dose 40 mg twice daily; may be increased to 240 mg daily (divided into 4 doses).
* IV: Starting dose 40 mg twice daily; may be increased to 240 mg daily (divided into 4 doses).
## Pediatric Dosing
Dosing in pediatric patients can vary based on age, weight, and indication. Consult specific pediatric guidelines or product labeling.
**GERD (6 months to 16 years):**
* Oral: 0.5-1.3 mg/kg/day once daily, not to exceed 40 mg/day.
**Erosive Esophagitis (5 years to 16 years):**
* Oral: 1.15-1.3 mg/kg/day once daily, not to exceed 40 mg/day.
## Dose Adjustments
* **Hepatic Impairment:** For severe hepatic impairment, a maximum dose of 20 mg once daily is recommended for oral formulations. For IV formulations, dose adjustment may be necessary; consult specific guidelines.
* **Renal Impairment:** No dose adjustment is typically required.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, flatulence.
* Serious: Clostridium difficile-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia (can be severe and may lead to cardiac arrhythmias, seizures), vitamin B12 deficiency, acute interstitial nephritis.
## Key Drug Interactions
* **Certain Antiretrovirals:** Reduced absorption of drugs like atazanavir and nelfinavir due to decreased gastric acidity.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel, diazepam, phenytoin.
* **Warfarin:** Increased INR and prothrombin time.
## Monitoring
* Electrolytes (magnesium, potassium, calcium), especially with prolonged use or in patients on diuretics.
* Renal function, particularly with long-term therapy.
* Bone mineral density in patients at risk for osteoporosis with long-term use.
* Signs and symptoms of C. difficile infection.
* Vitamin B12 levels with prolonged therapy.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal.
* For oral delayed-release tablets, do not crush or chew. They can be dispersed in 100 mL of apple juice or orange juice or 100 mL of water.
* IV pantoprazole is a powder for injection that requires reconstitution and further dilution. Ensure proper administration technique.
* Long-term PPI use is associated with increased risks of fractures, C. difficile infection, and hypomagnesemia. Consider the lowest effective dose and shortest duration necessary.
***
**Disclaimer:** This information is intended for healthcare professionals and should not replace professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.
